ADH-1 trifluoroacetate is primarily used in the field of cancer research and treatment. It functions as a cadherin antagonist, specifically targeting N-cadherin, which plays a crucial role in cell adhesion and signaling. By inhibiting N-cadherin, ADH-1 trifluoroacetate disrupts the communication between cancer cells and their microenvironment, potentially reducing tumor growth and metastasis. This compound is often investigated in preclinical and clinical studies for its efficacy in treating various cancers, including melanoma and other solid tumors. Its application is particularly significant in combination therapies, where it enhances the effectiveness of other anticancer agents by weakening the structural integrity of tumor tissues. Researchers also explore its potential in overcoming drug resistance, making it a valuable tool in the development of advanced cancer treatments.